ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

Bristol Myers Squibb reported phase 3 results showing that its bispecific antibody-drug conjugate izalontamab brengitecan significantly improved survival outcomes for previously treated triple-negative breast cancer patients in a China-based study. 

 

The EGFRxHER3-targeting therapy reduced the risk of death by 40% compared with physician-selected chemotherapy and extended median overall survival to 15.9 months versus 12.5 months in the control arm. The treatment also improved progression-free survival, with patients going a median of 8.5 months without disease progression compared with 3.1 months for chemotherapy recipients. “This is a very important drug,” said Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, who highlighted its potential across multiple tumor types. 

 

The results highlight the growing momentum behind next-generation oncology platforms and their potential to expand treatment options across the life sciences ecosystem.